【摘要】 目的观察北京降压0号和吲达帕胺(寿比山)治疗原发性高血压患者的长期疗效,以便进一步提高西北农村地区高血压控制率和治疗率。方法在陕西省、甘肃省、青海省和宁夏回族自治区的4个省区农村16个中心,选出符合试验要求的高危和很高危原发性高血压患者980人进行降压药物(寿比山组481例和北京降压0号组499例)的疗效观察以及血清学生化指标检测。结果在治疗1、3、7和12个月时与治疗前比较:北京降压0号组收缩压分别下降6.62、20.87、27.04和27.38mmHg,舒张压分别下降3.47、10.78、14.41和14.84mmHg;寿比山组收缩压分别下降6.31、20.14、24.71和24.94mmHg,舒张压分别下降3.68、9.74、12.43和13.58mmHg,与治疗前对比差别有统计学意义(P值均<0.01)。经过一年的治疗随访,血压控制率北京降压0号组增加了54.2%,寿比山组增加了52.6%。两组在研究期间均未观察到严重的毒副作用。结论长期应用北京降压0号或寿比山治疗农村原发性高血压患者均可以取得良好的血压控制效果,且性价比较好。更多还原

【Abstract】 Objective To evaluate the efficacy of Beijing Hypotensive No.0 and indapamide on essential hypertension in Northwestern rural areas.Methods Nine hundred eighty high-risk or very-high-rsik patients with essential hypertension were enrolled from 16 rural health service centers in 4 provinces(Shaan’xi,Gansu,Qinghai and Ningxia),to observe the therapeutic effects of antihypertensive drugs(group A,n=481,receiving indapamide;group B,n=499,receiving Beijing Hypotensive No.0),and to detect serological biochemical indicators.Results When compared with pretreatment,the systolic blood pressures of group B after 1,3,7,12 months of treatment decreased by 6.62,20.87,27.04,27.38 mm Hg,respectively,in group B,and by 6.31,20.14,24.71,24.94 mm Hg,respectively,in group A;the diastolic fell 3.47,10.78,14.41,14.84 mm Hg,respectively,in group B,and 3.68,9.74,12.43,13.58 mm Hg,respectively,in group A(P<0.01 compared with the baseline).No severe side effects were observed.Conclusion Long-term use of Beijing Hypotensive No.0 or indapamide,which has an excellent cost performance,can result in good effects in blood pressure control.更多还原